[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100287730":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":139,"collaborators":141,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":146,"sex":152,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":28,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":54,"whyStopped":28,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Groupe Hospitalier Diaconesses Croix Saint-Simon","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Control arm","ACTIVE_COMPARATOR","Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.\n\nThe regimen of administration of the chemotherapy is as following:\n\n* Carboplatin AUC 6 - IV - Day (D) 1\n* Paclitaxel 80mg \u002F m² - IV - D1, D8, D15\n\none cycle every 3 weeks",[13,14],"Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV)","Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV)",{"label":16,"type":17,"description":18,"interventionNames":19},"Experimental arm","EXPERIMENTAL","Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.\n\n* Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.\n* Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.\n\nThe regimen of administration of the chemotherapy is as following:\n\n* Cisplatin 80mg \u002F m² - IV or IP - D1\n* Epirubicin 60mg \u002F m² - IV - D3\n\none Cycle every 3 weeks.",[20,21],"Drug: CC0 - Cisplatin (IP) - Epirubicin (IV)","Drug: CC>0 - Cisplatin (IP\u002FIV)- Epirubicin (IV)",[23,29,32,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","CC0 - Carboplatin (IV) - Paclitaxel (IV)","(6 cycles)",[9],null,{"type":24,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"CC0 - Cisplatin (IP) - Epirubicin (IV)",[16],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"CC>0 - Carboplatin (IV)- Paclitaxel (IV)","* carboplatin (IV) - paclitaxel (IV) (3 cycles)\n* Interval surgery\n* Carboplatin (IV) - paclitaxel (IV) (3 cycles)",[9],{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":28},"CC>0 - Cisplatin (IP\u002FIV)- Epirubicin (IV)","* Cisplatin (IV) - Epirubicin (IV) (3 cycles)\n* Interval surgery :\n\n  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)\n  * if CC\\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)",[16],[41],{"name":42,"affiliation":43,"role":44},"Richard VILLET, MD","Groupe Hospitalier Diaconessess Croix Saint Simon","PRINCIPAL_INVESTIGATOR",[46,49],{"name":42,"role":47,"phone":48,"phoneExt":28,"email":28},"CONTACT","33 (0) 1 44 74 10 42",{"name":50,"role":47,"phone":28,"phoneExt":28,"email":28},"Delphine COCHEREAU, MD",[52,68,82,93,102,114,127],{"facility":53,"status":54,"city":55,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Centre Georges François Leclerc","RECRUITING","Dijon","France","FR",{"type":59,"coordinates":60},"Point",[61,62],5.01391,47.31344,{"lat":62,"lon":61},[65,67],{"name":66,"role":47,"phone":28,"phoneExt":28,"email":28},"Leïla BENGRINE, MD",{"name":66,"role":44,"phone":28,"phoneExt":28,"email":28},{"facility":69,"status":54,"city":70,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Institut Hospitalier Franco-Britannique","Levallois-Perret",{"type":59,"coordinates":72},[73,74],2.28864,48.89389,{"lat":74,"lon":73},[77,79,80],{"name":78,"role":47,"phone":28,"phoneExt":28,"email":28},"Aimery De GRAMONT, MD",{"name":78,"role":44,"phone":28,"phoneExt":28,"email":28},{"name":50,"role":81,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"facility":83,"status":54,"city":84,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Groupe Hospitalier Diaconesses Croix Saint Simon","Paris",{"type":59,"coordinates":86},[87,88],2.3488,48.85341,{"lat":88,"lon":87},[91,92],{"name":42,"role":47,"phone":28,"phoneExt":28,"email":28},{"name":42,"role":44,"phone":28,"phoneExt":28,"email":28},{"facility":94,"status":54,"city":84,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":95,"geoPoint":97,"contacts":98},"Hôpital Saint Antoine",{"type":59,"coordinates":96},[87,88],{"lat":88,"lon":87},[99,101],{"name":100,"role":47,"phone":28,"phoneExt":28,"email":28},"Romain COHEN, MD",{"name":100,"role":44,"phone":28,"phoneExt":28,"email":28},{"facility":103,"status":54,"city":104,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Hôpital Poissy Saint Germain","Poissy",{"type":59,"coordinates":106},[107,108],2.04952,48.92902,{"lat":108,"lon":107},[111,113],{"name":112,"role":47,"phone":28,"phoneExt":28,"email":28},"Cyrille HUCHON, MD",{"name":112,"role":44,"phone":28,"phoneExt":28,"email":28},{"facility":115,"status":54,"city":116,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"CHU Poitiers","Poitiers",{"type":59,"coordinates":118},[119,120],0.34348,46.58261,{"lat":120,"lon":119},[123,125],{"name":124,"role":47,"phone":28,"phoneExt":28,"email":28},"Nadia RABAN",{"name":126,"role":44,"phone":28,"phoneExt":28,"email":28},"Nadia RABAN, MD",{"facility":128,"status":54,"city":129,"state":28,"zip":28,"country":56,"countryCode":57,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Centre Hospitalier Senlis","Senlis",{"type":59,"coordinates":131},[132,133],2.58661,49.20724,{"lat":133,"lon":132},[136,138],{"name":137,"role":47,"phone":28,"phoneExt":28,"email":28},"Elisabeth CAROLA, MD",{"name":137,"role":44,"phone":28,"phoneExt":28,"email":28},{"type":140,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[142],{"name":143,"class":6},"GERCOR - Multidisciplinary Oncology Cooperative Group","100287730","phase-2-two-therapeutic-strategies-in-first-line-in-patients-with-epithelial-advanced-ovarian-cancer-100287730",false,"NCT03025477","Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer","Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer","CHIMOVIP","Inclusion Criteria:\n\n* Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to be performed in patients with pleural effusion.\n* Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion\n* Age ≥18 and \\\u003C 75 years old.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score \\\u003C 6 in patients \\> 70 years old).\n* Adequate blood count (test realized in the past 14 days before inclusion) : neutrophils \\> 1500\u002Fmm3, platelets \\> 150 000\u002Fmm3.\n* Creatinine clearance MDRD ≥ 60 mL\u002Fmin\n* Registration in a national health care system (CMU included).\n* Signed and dated informed consent.\n\nExclusion Criteria:\n\n* FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion.\n* Patient having received previous chemotherapy for ovarian cancer.\n* Left ventricular ejection fraction \\\u003C 50% before chemotherapy initiation\n* Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted)\n* Concomitant administration of prophylactic phenytoin or live attenuated viral vaccines such as yellow fever vaccine,\n* Patients with known hypersensitivity to any component of study drug\n* Patients without motivation or capacity to respect study requirements and constraints\n* Pregnancy or breast feeding women","FEMALE","18 Years","75 Years",{"count":156,"type":157},84,"ESTIMATED","INTERVENTIONAL",[160],"PHASE2","CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.",[163],"Ovarian Cancer, Epithelial",[165,166,167,168,169,170,171],"Intraperitoneal","Intravenous","Completeness of cytoreduction score","Carboplatin","Epirubicin","Paclitaxel","Cisplatin","2021-02-10",{"date":174,"type":175},"2021-02-11","ACTUAL",{"date":177,"type":175},"2016-10",{"date":179,"type":157},"2032-10",{"name":5,"class":6},7]